12 Comments
founding

Like many, I am looking at what to do with my ocrelizumab therapy - vaccine issues aside, I am not very happy with it (but maybe I am expecting too much).

Any chance we can get a series of posts with an uptodate low down on the efficacy and side effect distribution of the high efficacy DMTs?

I know we do not have any decent head to head trials but some trends emerge. Would love to see if my own research is valid.

Expand full comment

An interesting case study and probably a switch that a number of anti CD20 patients are considering. My question is, setting vaccine readiness aside, is there an optimal timeframe for commencing Alemtuzumab post anti CD20. Is it necessary to wait for repopulation of B-cells when there could actually be some benefit in surpressing them whilst the t-cells repopulate? And what would this mean for covid vulnerability? No vaccine protection is one thing but if t-cells are wiped by Alemtuzumab, do you become a sitting duck?

Expand full comment